Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mirati Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT00679133
First received: May 14, 2008
Last updated: January 6, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2011
  Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)